8th Feb 2016 15:14
Abzena plc
("Abzena", the "Company" or the "Group")
Exercise of Employee Share Options
Cambridge, UK, 8 February 2016 - Abzena plc (AIM: ABZA) announces that 7,335 new ordinary shares of £0.002 each in the Company (the "Ordinary Shares") have been issued and allotted
following the exercise of employee share options. The new Ordinary Shares rank pari passu with the Company's existing issued ordinary shares and have been admitted for trading on AIM under the Company's Block admission.
The Company's enlarged issued share capital will comprise 136,107,140 ordinary shares with voting rights. No shares are held in Treasury. The total number of voting rights in the Company is therefore 136,107,140.
This figure of 136,107,140 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer | +44 1223 903498 |
Cenkos Securities (Nominated Adviser and Broker) Christopher Golden / Ivonne Cantu | +44 20 7397 8900 |
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong | +44 20 7496 3000 |
Instinctif Partners Melanie-Toyne Sewell / Rozi Morris | +44 20 7457 2020 |
About Abzena
Abzena provides proprietary technologies and complementary services in the UK and US to enable the development and manufacture of biopharmaceutical products. The development of biopharmaceuticals is a growing area and requires specialist technology and expertise.
The Group comprises Antitope, PacificGMP, PolyTherics and TCRS, which between them have built a global customer base including the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
PacificGMP provides contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
TCRS is a contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.
Abzena (AIM: ABZA) has its main operations in Cambridge, UK, San Diego, CA, US and Bristol, Pennsylvania, US . For more information, please see www.abzena.com.
Related Shares:
Abzena